NOTV · Inotiv, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $117.65M | $120.88M | $130.68M | $124.32M | $119.88M | $105.79M | $119.03M | $122.75M | $172.67M | $151.46M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $17.64M | $18.49M | $17.88M | $17.15M | $19.15M | $16.78M | $19.80M | $19.93M | $26.57M | $29.04M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $14.08M | $13.79M | $13.98M | $13.82M | $14.18M | $14.12M | $14.15M | $14.25M | $13.86M | $9.83M |
| Operating Income | ($19.31M) | ($16.33M) | ($5.67M) | ($2.94M) | ($15.51M) | ($20.75M) | ($43.12M) | ($9.37M) | $8.78M | ($2.13M) |
| Interest Expense | $14.06M | $13.46M | $13.61M | $11.09M | $13.84M | $2.95M | $11.09M | $11.36M | $10.79M | $10.52M |
| Income Tax | ($1.28M) | ($1.64M) | ($1.19M) | ($1.11M) | ($2.18M) | ($6.86M) | ($6.36M) | ($3.49M) | ($2.38M) | ($2.47M) |
| Net Income | ($32.47M) | ($28.38M) | ($17.58M) | ($14.87M) | ($27.63M) | ($26.09M) | ($48.08M) | ($15.39M) | $1.84M | ($9.99M) |
| EPS - Basic | ($0.94) | ($0.83) | ($0.51) | ($0.44) | ($1.02) | ($1.00) | ($1.86) | ($0.60) | $0.07 | ($0.39) |
| EPS - Diluted | ($0.94) | ($0.83) | ($0.51) | ($0.44) | ($1.02) | ($1.00) | ($1.86) | ($0.60) | $0.07 | ($0.39) |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.18M | $12.73M | $21.74M | $19.30M | $38.04M | $21.43M | $32.70M | $22.00M | $35.49M | $24.60M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $65.13M |
| Inventory | $30.55M | $44.32M | $45.74M | $38.04M | $31.56M | $18.17M | $45.41M | $50.64M | $56.10M | $64.29M |
| Accounts Payable | $38.18M | $42.59M | $48.53M | $32.21M | $24.95M | $33.53M | $28.38M | $30.72M | $32.56M | $30.11M |
| Current Assets | $144.47M | $163.77M | $194.59M | $173.66M | $171.42M | $163.41M | $180.68M | $190.69M | $213.80M | $210.65M |
| Total Assets | $702.42M | $734.34M | $771.11M | $765.97M | $772.91M | $781.36M | $815.38M | $835.51M | $856.53M | $868.67M |
| Current Liabilities | $540.28M | $538.54M | $556.78M | $115.41M | $109.13M | $119.04M | $492.93M | $109.49M | $132.19M | $132.45M |
| Long-term Debt | $0 | $0 | $0 | $392.39M | $392.98M | $389.80M | $275.0K | $370.93M | $369.80M | $370.04M |
| Total Liabilities | $625.32M | $625.31M | $635.09M | $608.27M | $603.08M | $610.86M | $608.22M | $581.35M | $588.04M | $596.03M |
| Stockholders' Equity | $77.10M | $109.02M | $136.03M | $157.69M | $169.83M | $170.50M | $207.16M | $254.16M | $269.15M | $273.95M |
| Retained Earnings | ($691.66M) | ($659.19M) | ($630.81M) | ($604.68M) | ($589.79M) | ($562.16M) | ($517.18M) | ($469.11M) | ($453.28M) | ($444.84M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($5.43M) | - | - | ($4.50M) | - | - | ($6.54M) | - | - |
| Investing Cash Flow | - | ($5.18M) | - | - | ($4.46M) | - | - | ($4.04M) | - | - |
| Financing Cash Flow | - | $1.54M | - | - | $26.13M | - | - | ($2.92M) | - | - |
| CapEx | $2.10M | $5.18M | $4.01M | $5.47M | $4.46M | $4.42M | $7.02M | $5.57M | $4.48M | $9.55M |
| Free Cash Flow | - | ($10.61M) | - | - | ($8.96M) | - | - | ($12.12M) | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -16.4% | -13.5% | -4.3% | -2.4% | -12.9% | -19.6% | -36.2% | -7.6% | 5.1% | -1.4% |
| EBITDA margin | -4.4% | -2.1% | 6.4% | 8.8% | -1.1% | -6.3% | -24.3% | 4.0% | 13.1% | 5.1% |
| Net margin | -27.6% | -23.5% | -13.5% | -12.0% | -23.0% | -24.7% | -40.4% | -12.5% | 1.1% | -6.6% |
| Free cash flow margin | - | -8.8% | - | - | -7.5% | - | - | -9.9% | - | - |
| FCF / Net income | - | 0.37 | - | - | 0.32 | - | - | 0.79 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 15.0% | 15.3% | 13.7% | 13.8% | 16.0% | 15.9% | 16.6% | 16.2% | 15.4% | 19.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.6% | -3.9% | -2.3% | -1.9% | -3.6% | -3.3% | -5.9% | -1.8% | 0.2% | -1.2% |
| Return on equity | -42.1% | -26.0% | -12.9% | -9.4% | -16.3% | -15.3% | -23.2% | -6.1% | 0.7% | -3.6% |
| Return on invested capital | -19.8% | -11.8% | -3.3% | -0.4% | -2.2% | -2.9% | -16.4% | -1.2% | 1.1% | -0.3% |
| Liquidity | ||||||||||
| Current ratio | 0.27 | 0.30 | 0.35 | 1.50 | 1.57 | 1.37 | 0.37 | 1.74 | 1.62 | 1.59 |
| Quick ratio | 0.21 | 0.22 | 0.27 | 1.18 | 1.28 | 1.22 | 0.27 | 1.28 | 1.19 | 1.10 |
| Cash ratio | 0.03 | 0.02 | 0.04 | 0.17 | 0.35 | 0.18 | 0.07 | 0.20 | 0.27 | 0.19 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | 2.49 | 2.31 | 2.29 | 0.00 | 1.46 | 1.37 | 1.35 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.51 | 0.51 | 0.50 | 0.00 | 0.44 | 0.43 | 0.43 |
| Debt / EBITDA | - | - | 0.00 | 36.05 | - | - | - | 76.03 | 16.33 | 48.02 |
| Interest coverage | -1.4x | -1.2x | -0.4x | -0.3x | -1.1x | -7.0x | -3.9x | -0.8x | 0.8x | -0.2x |
| Equity multiplier | 9.11 | 6.74 | 5.67 | 4.86 | 4.55 | 4.58 | 3.94 | 3.29 | 3.18 | 3.17 |
| Liabilities / Assets | 0.89 | 0.85 | 0.82 | 0.79 | 0.78 | 0.78 | 0.75 | 0.70 | 0.69 | 0.69 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | 0.16 | 0.17 | 0.16 | 0.16 | 0.14 | 0.15 | 0.15 | 0.20 | 0.17 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | 157d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 44.0x | - |
| P / B | 0.1x | 0.2x | 0.4x | 0.5x | 0.7x | 0.3x | 1.4x | 0.4x | 0.3x | 0.4x |
| P / S | 0.1x | 0.2x | 0.4x | 0.6x | 0.9x | 0.4x | 2.4x | 0.8x | 0.5x | 0.7x |
| EV / EBITDA | - | - | 3.4x | 41.2x | - | - | - | 90.9x | 18.3x | 59.3x |
| Growth | ||||||||||
| Revenue growth (YoY) | -5.4% | 0.8% | 23.5% | 4.4% | -2.3% | -38.7% | -21.4% | 0.0% | 0.0% | 7.9% |
| Revenue CAGR (3y) | -8.1% | -0.5% | -8.9% | -4.0% | 12.5% | 66.6% | 85.2% | 90.0% | 122.1% | 111.5% |
| Revenue CAGR (5y) | 44.4% | 46.5% | 52.7% | 50.7% | 56.1% | 57.7% | 66.4% | 70.1% | 95.5% | 91.1% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -557.2% | -5.3% | 72.7% | 93.2% | -65.5% | - | -1929.0% | 89.7% | 83.5% | - |
| Net income growth (YoY) | -118.4% | -2.7% | 32.6% | 69.1% | -79.6% | - | -381.1% | 82.4% | - | -64.2% |
| EPS growth (YoY) | -113.6% | 18.6% | 49.0% | 76.3% | -70.0% | - | -376.9% | 82.4% | - | -62.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -18.5% | - | - | 26.1% | - | - | 23.2% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -51.1% | -35.8% | -20.2% | -23.9% | -33.2% | -36.7% | -24.4% | -9.5% | -25.3% | -55.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$513.02M totalResearch Models And Services Segment$325.08M · 63.4%
Discovery And Safety Assessment Segment$187.94M · 36.6%
Product / service
$513.02M totalProduct$280.16M · 54.6%
Service$232.87M · 45.4%
Geographic
$513.02M totalUS$447.98M · 87.3%
NL$35.48M · 6.9%
Other Than United States And Netherlands$29.56M · 5.8%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing Inotiv against the 5 most active filers in the same SIC group.